DBVT
USDDBV Technologies S.A. American Depositary Shares
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$14.050
고가
$15.010
저가
$14.050
거래량
0.07M
기업 기본 정보
시가총액
521.2M
산업
생명공학
국가
France
거래 통계
평균 거래량
0.10M
거래소
NCM
통화
USD
52주 범위
관련 뉴스
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a clinical-stage
HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $20
HC Wainwright & Co. analyst Andrew S. Fein maintains DBV Technologies with a Buy and raises the price target from $16 to $20.
